Articles from VectorY Therapeutics

VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and Shape Therapeutics Inc., a biotechnology company harnessing AI and RNA technologies to engineer next-generation genetic medicines, today announced that they have entered into an option and license agreement. The agreement grants VectorY an exclusive option to evaluate Shape’s deep-brain penetrating adeno-associated virus (AAV) capsid, SHP-DB1, for vectorized antibody payloads against three therapeutic targets. Upon successful evaluation, VectorY may obtain an exclusive license to SHP-DB1 for delivery of vectorized antibodies against these targets.

VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships.

VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the presentation of new preclinical data on one of its two therapeutic vectorized antibodies for ALS, VTx-001, at the Target ALS Annual Meeting in Boston, Massachusetts taking place between May 6-8, 2025.

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four featured data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana.

VectorY Therapeutics, a biotechnology company advancing vectorized antibody therapies for neurodegenerative diseases, today announced the appointment of Olga Uspenskaya-Cadoz, M.D., Ph.D., as Chief Medical Officer (CMO).

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer.

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Adam Rosenberg as the new Chair of the Board.

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.

VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neuro-degenerative and muscular disorders through vectorized antibodies, today announces participation in three upcoming conferences.

VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the presentation of two posters at the American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. on May 16-19, 2022. Members of the VectorY team will attend the conference in person and be available to discuss the posters.